MRNA

MRNA

USD

Moderna Inc. Common Stock

$23.750-0.890 (-3.612%)

Preço em tempo real

Healthcare
Biotecnologia
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$24.640

Máximo

$25.150

Mínimo

$23.710

Volume

13.75M

Fundamentos da empresa

Capitalização de mercado

9.3B

Setor

Biotecnologia

País

United States

Estatísticas de negociação

Volume médio

11.01M

Bolsa de valores

NMS

Moeda

USD

Faixa de 52 semanas

Mínimo $23.15Atual $23.750Máximo $56.695

Notícias relacionadas

CNBC

November trading, Berkshire's cash hoard, Big Tech's ad revenue and more in Morning Squawk

Here are five key things investors need to know to start the trading day.

Ver mais
November trading, Berkshire's cash hoard, Big Tech's ad revenue and more in Morning Squawk
Analyst Upgrades

UBS Maintains Buy on Moderna, Lowers Price Target to $40

UBS analyst Eliana Merle maintains Moderna with a Buy and lowers the price target from $70 to $40.

Ver mais
UBS Maintains Buy on Moderna, Lowers Price Target to $40
AccessWire

Moderna Named a Top Employer by Science for Eleventh Consecutive Year

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2025 Top Employers

Ver mais
Moderna Named a Top Employer by Science for Eleventh Consecutive Year
Analyst Upgrades

JP Morgan Maintains Underweight on Moderna, Lowers Price Target to $25

JP Morgan analyst Jessica Fye maintains Moderna with a Underweight and lowers the price target from $26 to $25.

Ver mais
JP Morgan Maintains Underweight on Moderna, Lowers Price Target to $25
Analyst Upgrades

Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven and financial guidance.

Ver mais
Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection
AccessWire

Moderna to Host Investor Event - Analyst Day

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. today announced that it will host its Investor Event - Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025.The event will include

AccessWire

Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint

Company to discontinue development of mRNA-1647 in congenital CMVCompany will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patientsCompany does not anticipate any impact to its 2025

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.